Phosphate intake, hyperphosphatemia, and kidney function.
Rubio-Aliaga I, Krapf R.
Pflugers Arch. 2022 Aug;474(8):935-947. doi: 10.1007/s00424-022-02691-x. Epub 2022 May 5.
PMID:35511366
Phosphate disorders and clinical management of hypophosphatemia and hyperphosphatemia.
García Martín A, Varsavsky M, Cortés Berdonces M, Ávila Rubio V, Alhambra Expósito MR, Novo Rodríguez C, Rozas Moreno P, Romero Muñoz M, Jódar Gimeno E, Rodríguez Ortega P, Muñoz Torres M.
Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management.
Raju S, Saxena R.
Nutrients. 2025 May 5;17(9):1587. doi: 10.3390/nu17091587.
PMID:40362897
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE, Rosenbaum DP, Yang Y, Chertow GM.
J Am Soc Nephrol. 2021 Jun 1;32(6):1465-1473. doi: 10.1681/ASN.2020101398. Epub 2021 Mar 25.
PMID:33766811
Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches.
Anand A, Aoyagi H.
Medicina (Kaunas). 2023 May 16;59(5):959. doi: 10.3390/medicina59050959.
PMID:37241191
The Causes of Hypo- and Hyperphosphatemia in Humans.